ERYtech Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lyon France (2004)

Organization Overview

First Clinical Trial
2006
NCT00723346
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ERYtech Pharma

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 3)

Hypersensitivity (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 1)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Recurrence (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 10